Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 16, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12951-018-0386-6
Keywords
Bio-nanocapsule; Hepatitis B virus; Vaccine; Dendritic cell; In vivo targeting; Protective immunity
Funding
- Japan Society for the Promotion of Science (JSPS) KAKENHI [16H06314, 17J08534]
- Japan Agency for Medical Research and Development (AMED) [17cm0106214h0002, 17fk0310105h0001]
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Mishima Kaiun Memorial Foundation
- Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN)
- Grants-in-Aid for Scientific Research [17J08534] Funding Source: KAKEN
Ask authors/readers for more resources
Background: Various nanocarriers have been used to deliver subunit vaccines specifically to dendritic cells (DCs) for the improvement of immunogenicity. However, due to their insufficient DC priming ability, these vaccines could not elicit effective innate immunity. We have recently developed a DC-targeting bio-nanocapsule (BNC) by displaying anti-CD11c IgGs via protein A-derived IgG Fc-binding Z domain on the hepatitis B virus envelope L protein particles (alpha-DC-ZZ-BNC). Results: After the chemical modification with antigens (Ags), the alpha-DC-ZZ-BNC-Ag complex could deliver Ags to DCs efficiently, leading to effective DC maturation and efficient endosomal escape of Ags, followed by Ag-specific T cell responses and IgG productions. Moreover, the alpha-DC-ZZ-BNC modified with Japanese encephalitis virus (JEV) envelope-derived D3 Ags could confer protection against 50-fold lethal dose of JEV injection on mice. Conclusion: The alpha-DC-ZZ-BNC-Ag platform was shown to induce humoral and cellular immunities effectively without any adjuvant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
